ÌÇÐÄvlog

Guha et al studied samples from 2 multiple-center discovery cohorts to determine whether a novel deletion at distal 16p11.2 is implicated in schizophrenia.

To assess cognitive developmental trajectories in youth and the risk for psychosis in adulthood, MacCabe et al performed a longitudinal cohort study of 4 Swedish cohorts. Verbal, spatial, and inductive ability were recorded at age 13 years and at army conscription, as well as admissions for nonaffective or affective psychoses in adulthood.

Steiner et al used serum samples for comparison of N-methyl-D-aspartate glutamate receptor (NMDA-R) antibodies in 121 patients with schizophrenia with those antibodies in patients with major depression or borderline personality disorder, as well as healthy controls.

In a double-blind, placebo-controlled, crossover study with repeated functional magnetic resonance imaging, Furey et al determine if baseline brain activity when processing emotional information can predict treatment response to scopolamine in major depressive disorder.

Croarkin et al compare measures of cortical excitability and inhibition with 4 different paradigms in a group of children and adolescents with major depressive disorder (MDD) vs healthy controls.

Using a dual-frame national sample of adolescents from the National Comorbidity Survey Replication Adolescent Supplement, Nock and coauthors estimate the lifetime prevalence of suicidal behaviors among US adolescents and the associations of retrospectively reported, temporally primary DSM-IV disorders with the subsequent onset of suicidal behaviors.

Chang et al explore the relative contribution of genetic and environmental influences on symptoms of attention problems from childhood to early adulthood.

In a longitudinal prospective cohort study, McKetin and coauthors determine the change in the probability of psychotic symptoms occurring during periods of methamphetamine use among 278 participants 16 years of age or older who met DSM-IV criteria for methamphetamine dependence on entry to the study but who did not meet DSM-IV criteria for lifetime schizophrenia or mania.

To determine the use of the Individual Burden of Illness Index for Depression (IBI-D) for assessing treatment efficacy for depressed patients, Cohen and colleagues used complete data on depressive symptom severity, functioning, and quality of life at entry and exit of level 1 of the Sequenced Treatment Alternatives to Relieve Depression study to calculate IBI-D and self-rating scale changes.

Conrod and coauthors report 24-month outcomes of the Adventure trial in which school staff provided interventions to students with anxiety sensitivity, hopelessness, impulsivity, and sensation seeking.

To determine the use of the Individual Burden of Illness Index for Depression (IBI-D) for assessing treatment efficacy for depressed patients, Cohen and colleagues used complete data on depressive symptom severity, functioning, and quality of life at entry and exit of level 1 of the Sequenced Treatment Alternatives to Relieve Depression study to calculate IBI-D and self-rating scale changes.